Amgen Inc. raised its full-year guidance after third-quarter results beat expectations, a positive sign in light of hurdles from Washington and the risks of increased competition.
The biotechnology company now expects adjusted profit of as much as $21.40 per share, up from its earlier forecast of as much as $21.30 per share, the second profit guidance boost this year. Revenue is expected to be as much as $36.6 billion. The new guidance takes existing tariffs into account, though future levies or pricing actions aren’t considered.
Amgen outperformed in the third quarter thanks to new drugs including inflammation medicines Pavblu and ...
